SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing extreme volatility, with the community actively debating whether it's a short squeeze or a pump and dump. The stock's low float and history of reverse splits are fueling speculation, with some comparing it to previous high-flying stocks like HKD and TGL. Traders are closely watching for offering news and momentum above key price levels, while others are suggesting it's overvalued and due for a correction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending amid speculation of acquiring Warner Bros. Discovery, potentially creating a streaming giant with HBO content; the community debates the deal's implications, regulatory hurdles, and whether it's a strategic win or overreach. Community sentiment seems mixed, with some anticipating a significant boost if the acquisition is approved, while others express concerns regarding regulatory hurdles and market saturation.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TGL is trending due to a recent reverse split and resulting small float, leading to high volatility and discussions of potential short squeezes. The community is comparing TGL to other high-flying stocks like $SMX, with some anticipating a similar explosive run. Bullish sentiment is fueled by the company's shift towards fintech and AI, with potential catalysts including new product rollouts and partnership announcements.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending due to increased social media and community attention, with traders actively discussing a potential short squeeze and comparing it to recent runs of other low float stocks. The stock's high short interest and cost to borrow are key talking points, with some believing it has the potential for significant upward movement. However, caution is advised due to the company's history of reverse splits and volatile price action.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Traders are actively discussing Adobe's ($ADBE) recent performance, with some citing technical indicators suggesting a bullish trend, while others express frustration with the stock's inability to sustain gains. Community sentiment appears mixed amidst discussions around AI competition, potential undervaluation, and upcoming earnings. Chatter includes opinions on management, potential acquisitions, and speculation on future price movements.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices have been volatile, with traders actively discussing potential entry points and swing trading strategies. Community members are weighing factors like weather forecasts, storage levels, and technical indicators to gauge short-term movements. Some traders express caution, citing the potential for price manipulation and the impact of contract rollovers.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid speculation of a short squeeze, fueled by investor Martin Shkreli's bullish stance and a $100 near-term price target. The community is actively discussing the company's potential in photonics and comparing it to recent high-flying stocks like $SMX. With high volume and rising interest, traders are closely watching for continued upward momentum.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending amid speculation of a potential acquisition by Netflix, sparking debates about the deal's value and regulatory hurdles. Community chatter revolves around competing bids from Paramount and Comcast, with some expressing concerns over potential market manipulation and the fairness of the bidding process. Discussions also include the potential impact on streaming competition and the future of WBD's assets.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors debate its valuation after Q3 earnings and revenue beat estimates. While subscription growth is fueling positive sentiment and multiple analysts upgraded the stock, some community members point to negative cash flow and strong resistance around the $90 mark. Discussions also include potential catalysts from AI and strategic partnerships.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending due to news of a $1.5 billion public offering, sparking debate about dilution and its impact on the stock's potential S&P 500 inclusion. While some investors express concerns about the timing and potential short-term pain, others speculate the capital raise positions the company for future growth, potentially through acquisitions, and ultimately strengthens its long-term prospects. Community chatter also highlights differing opinions on management's strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GMAB $30.05 
https://stocktwits.com/G101SPM/message/569781615 
UPDATE:  
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024). 
 
Full prescribing information for Epkinly will be posted on Drugs@FDA. 
 
Approval of epcoritamab-bysp with lenalidomide and rituximab (R2) was based on EPCORE FL-1 (Study M20-638; NCT05409066), a randomized, open-label trial that enrolled 488 patients with relapsed or refractory FL. Patients were randomized (1:1) to receive epcoritamab-bysp plus R2 or R2 alone. Patients had a median of 1 prior line of systemic therapy (range: 1 to 7); 24% and17% had two and three or more prior lines, respectively. 
 
Efficacy was established based on progression free survival (PFS) and overall response rate (ORR) as assessed by an independent review committee (IRC) using Lugano 2014 Criteria. The study demonstrated superiority of PFS and ORR in the epcoritamab-bysp arm. The PFS hazard ratio was 0.21 (95% CI: 0.13, 0.33; p-value &lt;0.0001). The median PFS was not reached (NR) (95% CI: 21.9 months, NR) in the epcoritamab-bysp arm and was 11.2 months (95% CI: 10.5, NR) in the control arm. The ORR was 89% (95% CI: 84, 93) in the epcoritamab-bysp arm and 74% (95% CI: 68, 79) in the control arm. 
 
The prescribing information includes boxed warnings for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as warnings and precautions for infections and cytopenias. Serious adverse reactions occurred in 51% of the patients in the epcoritamab-bysp arm, including serious infections in 28%. CRS occurred in 24% of patients, including serious CRS in 12%. ICANS occurred in 0.8%. 
 
The recommended regimen for epcoritamab-bysp in combination with R2 consists of epcoritamab-bysp administered subcutaneously for up to twelve 28-day cycles, with lenalidomide on Days 1-21 of each cycle and rituximab for 5 cycles. The recommended epcoritamab-bysp dosage is a 3 step-up dosage schedule in Cycle 1 (0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15, and 48 mg on Day 22), followed by weekly dosing of 48 mg in Cycle 2 and 3, then every 4-week dosing of 48 mg in Cycles 4 to 12. 
 
This review was conducted as a Summary Review and used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. 
 
This application was granted breakthrough designation, priority review, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.

GMAB $29.52 bid. BUY/NEW LONG POSITION carries SPM 87.86 tag to $40 EXIT.

Stocktwits

Northridge Company (@G101SPM) | Stocktwits

StockTwits Web

GENMAB A/S

 
UPDATE:  
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024). 
 
Full prescribing information for Epkinly will be posted on Drugs@FDA. 
 
Approval of epcoritamab-bysp with lenalidomide and rituximab (R2) was based on EPCORE FL-1 (Study M20-638; NCT05409066), a randomized, open-label trial that enrolled 488 patients with relapsed or refractory FL. Patients were randomized (1:1) to receive epcoritamab-bysp plus R2 or R2 alone. Patients had a median of 1 prior line of systemic therapy (range: 1 to 7); 24% and17% had two and three or more prior lines, respectively. 
 
Efficacy was established based on progression free survival (PFS) and overall response rate (ORR) as assessed by an independent review committee (IRC) using Lugano 2014 Criteria. The study demonstrated superiority of PFS and ORR in the epcoritamab-bysp arm. The PFS hazard ratio was 0.21 (95% CI: 0.13, 0.33; p-value <0.0001). The median PFS was not reached (NR) (95% CI: 21.9 months, NR) in the epcoritamab-bysp arm and was 11.2 months (95% CI: 10.5, NR) in the control arm. The ORR was 89% (95% CI: 84, 93) in the epcoritamab-bysp arm and 74% (95% CI: 68, 79) in the control arm. 
 
The prescribing information includes boxed warnings for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as warnings and precautions for infections and cytopenias. Serious adverse reactions occurred in 51% of the patients in the epcoritamab-bysp arm, including serious infections in 28%. CRS occurred in 24% of patients, including serious CRS in 12%. ICANS occurred in 0.8%. 
 
The recommended regimen for epcoritamab-bysp in combination with R2 consists of epcoritamab-bysp administered subcutaneously for up to twelve 28-day cycles, with lenalidomide on Days 1-21 of each cycle and rituximab for 5 cycles. The recommended epcoritamab-bysp dosage is a 3 step-up dosage schedule in Cycle 1 (0.16 mg on Day 1, 0.8 mg on Day 8, 3 mg on Day 15, and 48 mg on Day 22), followed by weekly dosing of 48 mg in Cycle 2 and 3, then every 4-week dosing of 48 mg in Cycles 4 to 12. 
 
This review was conducted as a Summary Review and used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. 
 
This application was granted breakthrough designation, priority review, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.